Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of VX-814 in PiZZ Alpha-1 Antitrypsin Deficiency
2019-003650-92Phase 2Terminated
- Sponsor
- Vertex Pharmaceuticals
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alpha-1 antitrypsin deficiency (AATD) and airway morbidity comparing VX-814 with Placebo (2 arms). Primary endpoint: Change from baseline in plasma functional AAT levels at Day 28. Started Dec 2019; status: terminated.
02
Drugs
VX-814
03
Conditions
alpha-1 antitrypsin deficiency (AATD)airway morbidity
Beyond the preview
Go deeper on 2019-003650-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003650-92.